



Supporting you through your treatment

This booklet will help provide answers to some of your questions about UDENYCA®

- What is UDENYCA®?
- How UDENYCA® can lower the risk of infection
- How you'll be given UDENYCA®
- Financial support available for UDENYCA®

What is UDENYCA®?

UDENYCA® is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body's fight against infection.

IMPORTANT SAFETY INFORMATION

Do not take UDENYCA® if you have had a serious allergic reaction to pegfilgrastim or filgrastim products.

Please see additional Important Safety Information throughout this brochure, and [click here for Full Prescribing Information, Patient Information, and Instructions for Use.](#)




Let's get started

Your doctor has prescribed UDENYCA®

UDENYCA® increases your white blood cell count and helps your body fight infection and febrile neutropenia.

Your chemotherapy treatment can help stop cancer cells from growing, but can also lower your white blood cell count. A low white blood cell count can put you at risk for infection and a life-threatening complication called febrile neutropenia (low white blood cell count with fever).



White blood cells help your body fight infection. A low white blood cell count can put you at risk for infection.

UDENYCA® boosts the growth of white blood cells, helping your body fight off infection, and may prevent febrile neutropenia.

IMPORTANT SAFETY INFORMATION CONT'D

What are possible side effects of UDENYCA®?

UDENYCA® may cause serious side effects, including:

- **Spleen rupture:** Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
- **A serious lung problem called Acute Respiratory Distress Syndrome (ARDS):** Call your healthcare provider or get emergency care right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.

Please see additional Important Safety Information throughout this brochure, and [click here for Full Prescribing Information, Patient Information, and Instructions for Use.](#)



UDENYCA®
pegfilgrastim-cbqv



[Click here](#)
or scan this
code for more
information
about your
treatment.

How will I know if I have an infection?

It's important to take your temperature

Often the only sign of infection after chemotherapy may be a fever (100.4° F [38.0° C] or higher). Take your temperature any time you don't feel well or as recommended by your doctor.

If you develop a fever, it is a medical emergency, and you must call your healthcare team immediately or go to the emergency room at your local hospital.

Other signs and symptoms of infection include chills, shortness of breath, sore throat, stiff neck, and burning or pain with urination. Talk to your healthcare team about signs and symptoms to look out for.

Did you know?

The risk for developing febrile neutropenia is highest 7 to 12 days after you receive chemotherapy.

7-12
DAYS

IMPORTANT SAFETY INFORMATION CONT'D

What are possible side effects of UDENYCA®?

UDENYCA® may cause serious side effects, including:

- **Serious allergic reactions:** UDENYCA® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using UDENYCA® and call your healthcare provider or get emergency medical help right away.

Please see additional Important Safety Information throughout this brochure, and [click here for Full Prescribing Information, Patient Information, and Instructions for Use.](#)

UDENYCA®
pegfilgrastim-cbqv

Common side effects



The most common side effects of UDENYCA® are:



BONE PAIN



ARM PAIN



LEG PAIN

These are not all the possible side effects of UDENYCA®. Please see Important Safety Information throughout this brochure and contact your healthcare provider for medical advice about side effects.

Managing Side Effects

Strong medicine can sometimes have strong side effects. Talk to your doctor about any discomfort you may experience. Together, you can decide the best way to manage side effects so you can stay on track with your treatment.



IMPORTANT SAFETY INFORMATION CONT'D

What are possible side effects of UDENYCA®?

UDENYCA® may cause serious side effects, including:

- **Sickle cell crises:** You may have a serious sickle cell crisis if you have a sickle cell disorder and receive UDENYCA®. Serious sickle cell crises have happened in people with sickle cell disorders receiving pegfilgrastim that has sometimes led to death. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
- **Kidney injury (glomerulonephritis):** UDENYCA® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
 - Swelling of your face or ankles
 - Blood in your urine or dark colored urine
 - You urinate less than usual
- **Increased white blood cell count (leukocytosis):** Your healthcare provider will check your blood during treatment with UDENYCA®.

Please see additional Important Safety Information throughout this brochure, and [click here for Full Prescribing Information, Patient Information, and Instructions for Use.](#)

 **UDENYCA®**
pegfilgrastim-cbqv

How will I receive UDENYCA®?

UDENYCA® is usually given as an injection at your healthcare clinic the day after chemotherapy.

An in-clinic injection allows for a next-day follow-up with your healthcare team. Let your healthcare team know how you're feeling and get answers to any questions you may have.

Treatment Schedule

UDENYCA® will usually be given with every chemotherapy cycle.

For example, if you have 6 cycles of chemotherapy, you may receive 6 injections of UDENYCA®.



IMPORTANT SAFETY INFORMATION, CONT'D

What are possible side effects of UDENYCA®?

UDENYCA® may cause serious side effects, including:

- **Decreased platelet count (thrombocytopenia):** Your healthcare provider will check your blood during treatment with UDENYCA®. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with UDENYCA®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.

Please see additional Important Safety Information throughout this brochure, and [click here for Full Prescribing Information, Patient Information, and Instructions for Use.](#)



An FDA-approved biosimilar

UDENYCA® is a biosimilar. Biosimilars are safe and effective alternatives to the original approved treatments.

Biosimilars are “similar” to medications called biologics, which are made from living cells. UDENYCA® is a biosimilar of the medication Neulasta® (pegfilgrastim).

To gain FDA approval, UDENYCA® proved that:

- ✓ There were no differences in terms of safety and effectiveness vs Neulasta®
- ✓ It was highly similar to Neulasta® in terms of structure and function



Biosimilars are not the same as generics. Unlike generics, which are made from chemical processes to match an original branded treatment, biosimilars are made from living cells. Because of this, no two batches are exactly the same. A biosimilar is a highly similar version of a reference biologic, with no clinically meaningful differences in safety, purity, or effectiveness.

Biosimilars have lowered the cost of many treatments and have made medications more affordable for patients and the healthcare system.



[Click here or scan this code to learn how UDENYCA® may reduce treatment costs](#)

IMPORTANT SAFETY INFORMATION, CONT'D

What are possible side effects of UDENYCA®?

UDENYCA® may cause serious side effects, including:

- **Capillary Leak Syndrome:** UDENYCA® can cause fluid to leak from blood vessels into your body's tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
 - Swelling or puffiness and are urinating less than usual
 - Trouble breathing
 - Swelling of your stomach-area (abdomen) and feeling of fullness
 - Dizziness or feeling faint
 - A general feeling of tiredness

Please see additional Important Safety Information throughout this brochure, and [click here for Full Prescribing Information, Patient Information, and Instructions for Use.](#)



UDENYCA®
pegfilgrastim-cbqv



Financial support is available

UDENYCA Solutions™, part of the Coherus Solutions™ family of support services, offers a range of financial assistance programs for patients who are prescribed UDENYCA®.

Co-pay Savings Program

- The Co-pay Savings Program may cover out-of-pocket expenses associated with UDENYCA® for eligible patients with commercial insurance.
 - **Pay as little as \$0 per dose** of UDENYCA® with a maximum annual benefit of \$15,000 for drug costs per calendar year.*

Patient Assistance Program

- UDENYCA® may be available to you at no cost if you are uninsured, functionally underinsured, or are a traditional Medicare FFS patient experiencing financial hardship.*

Ask your doctor's office to help you apply to UDENYCA® financial support programs.

Independent Foundation Support

- UDENYCA Solutions™ may be able to help you find financial support through charitable foundations or you can choose to contact these independent assistance foundations directly.



Learn more about support and eligibility.
Scan this code, click here to visit UdenycaSolutions.com,
or call 1-844-4-UDENYCA (1-844-483-3692).



*Patients covered under Medicare, Medicaid, or any federal or state-funded program are not eligible for the Coherus Solutions™ Co-pay Savings Program. The Co-pay Savings Program ONLY covers the cost of UDENYCA® and does not cover costs associated with the office visit.

Eligibility requirements, type of assistance, and application process varies. Other restrictions apply, see Terms & Conditions at UDENYCASolutions.com. The Co-pay Savings Program and the Patient Assistance Program are subject to change or discontinuation without notice. This is not health insurance.





[Click here](#) or scan this code for more information about your treatment.

IMPORTANT SAFETY INFORMATION, CONT'D

What are possible side effects of UDENYCA[®]?

UDENYCA[®] may cause serious side effects, including:

- **Myelodysplastic syndrome and acute myeloid leukemia:** If you have breast cancer or lung cancer, when UDENYCA[®] is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with UDENYCA[®].
- **Inflammation of the aorta (aortitis):** Inflammation of the aorta (the large blood vessel that transports blood from the heart to the body) has been reported in patients who received pegfilgrastim. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.
- **Bone Imaging (Nuclear Imaging):** The formation of certain blood cells may increase and can be associated with short term changes in bone imaging. Your doctor should consider this when interpreting bone imaging results.

The most common side effects of UDENYCA[®] are pain in the bones, arms, and legs. These are not all the possible side effects of UDENYCA[®].

Call your healthcare provider for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or notify the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the [Patient Information](#) for UDENYCA[®], and discuss it with your doctor. The physician [Prescribing Information](#) is also available.

Please see additional Important Safety Information throughout this brochure, and [click here](#) for Full [Prescribing Information](#), [Patient Information](#), and [Instructions for Use](#).